ProFACT News

ProFACT Proteomics, Inc. Presents Poster at the CHI ADAPT 2009 Conference in Washington, D.C.

09/24/2009

ProFACT Proteomics, Inc. Presents Poster at the CHI ADAPT 2009 Conference in Washington, D.C.

Monmouth Junction, NJ, September 24, 2009: Matthew Kuruc, President of ProFACT Proteomics, Inc., presented a poster entitled “Molecular Profiling with SeraFILE™ - Prospecting for Conformational Variants” at Cambridge Healthtech Institute’s ADAPT 2009, Accelerating Development and Advancing Personal Therapy, a three day conference held in Washington, D.C.

The poster describes the SeraFILE™ platform, a proprietary, surface-based separations reagent set and associated exploratory protocols which addresses problems of functional proteomic prospecting for drug and biomarker discovery and development.

The poster, in document format, may be downloaded from the ProFACT Proteomics website at http://www.profactproteomics.com

About ProFACT Proteomics, Inc.
ProFACT Proteomics, Inc. is a privately held early-stage corporation which applies its enabling proprietary Proteomics technology, for development of therapeutics, diagnostics and personalized medicine, principally for cancer. Through partnership and service agreements, ProFACT offers SeraFILE™ for Functional Proteomics in four key areas for Drug and Biomarker development: 1) reduction of protein complexity and sub-proteome creation; 2) Rational Proteome Prospecting™, to enrich and isolate functional activity; 3) Conformerics™, to generate drug screening assays based on enzyme sub-states or conformers; and 4) Rational Genome to Proteome Prospecting™, for prospecting into protein expression based on gene expression data.